Pharmacoeconomic review report: Dapagliflozin (Forxiga)
Dapagliflozin (Forxiga) is an oral antihyperglycemic drug of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor class. This CADTH Common Drug Review (CDR) focuses on dapagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) to improve glycemic control when added on to metfor...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, April 2016
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Dapagliflozin (Forxiga) is an oral antihyperglycemic drug of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor class. This CADTH Common Drug Review (CDR) focuses on dapagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) to improve glycemic control when added on to metformin and a sulfonylurea for patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea and for whom insulin is not an option |
|---|---|
| Physical Description: | 1 PDF file (various pagings) illustrations |